Q3 2009 AMERICAN ORIENTAL BIOENGR INC Earnings Release - After Market Close

Earnings Announcements for Monday, November 16CompanySymbolTimeConferenceCallA.P. Pharma Inc.APPABefore Market OpenACE MARKETING & PROMOTIONS INCAMKT.OBAfter Market CloseACKERMANS & VAN HAAREN SAAVHNF.PKTime Not SuppliedADA ES INCADESBefore Market OpenAdvanced Environmental Recycling TechnologiesAERTTime Not SuppliedAethlon Medical Inc.AEMD.OBTime Not SuppliedAMBIENT CORPABTG.OBTime Not SuppliedAMERICAN DAIRY INCADYBefore Market OpenAmerican Metal & Technology, Inc.AMGY.OBTime Not SuppliedAMERICAN ORIENTAL BIOENGR INCAOBAfter Market CloseListenAMERICAN SPECTRUM REALTY INCAQQBefore Market OpenAnderson Energy Ltd.AXL.TOBefore Market OpenAnesiva Inc.ANSVAfter Market CloseARCA biopharma, Inc.ABIOAfter Market CloseARCADIA RES INCKADBefore Market OpenASIATRAVEL.COM HLDGS5AM.SIAfter Market CloseAssured GuarantyAGO...
Click here to read the whole Article (external link)

AMERICAN ORIENTAL BIOENGINEERING INC Files SEC form 10-K/A, Annual Report

ITEM 7. Management's Discussion and Analysis of Financial Condition and Results of Operations All of the financial information presented in this Item 7 has been adjusted to reflect the restatement of our consolidated financial statements as of and for the fiscal years ended December 31, 2008 and December 31, 2007. Specifically, we have restated our consolidated balance sheets and the related consolidated statements of income, consolidated statements of stockholders' equity and consolidated statements of cash flows as of and for the years ended December 31, 2008 and 2007. The restatement is more fully described in the "Explanatory Note" immediately preceding Part I, Item 1 and in Note 4 "Restatement of Consolidated Financial Statements," which is included in "Financial Statements and Supplementary Data" in Item 8 of this Form 10-K/A. You should read the following discussion in conjunction with our consolidated financial statements and related notes included elsewhere in this annual report on Form 10-K/A. This discussion contains forward-looking statements that are based on management's current expectations, estimates and projections about our business and operations. Our actual results may differ materially from those currently anticipated and expressed in such forward-looking statements. See " - Forward-Looking Statements." As used in this report, the terms "Company", "we", "our", "us" and "AOB" refer to American Oriental Bioengineering, Inc., a Nevada corporation. PRELIMINARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report contains forward-looking statements within the meaning of the federal securities laws. These include statements about our expectations, beliefs, intentions or strategies for the future, which we indicate by words or phrases such as "anticipate," "expect," "intend," "plan," "will," "we b...
Click here to read the whole Article (external link)

American Oriental Bioengineering Reports Third Quarter 2009 Financial Results

NEW YORK, Nov. 16 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB - News), ("the Company" or "AOBO"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products, today announced financial results for the third quarter ended September 30, 2009. Third Quarter 2009 Financial PerformanceRevenue in the third quarter of 2009 increased 11.7% to $78.8 million from $70.6 million in the third quarter of 2008, reflecting continued demand for the Company's core pharmaceutical and nutraceutical products. Revenue from pharmaceutical products increased 6.3% to $66.0 million from $62.1 million in the third quarter of 2008. Revenue from prescription pharmaceutical products increased 22.7% to $29.8 million during the third quarter of 2009, reflecting a year over year increase in sales from prescription formulated Jinji capsule, Boke and CCXA products, which offset declines in sales of Shuanghuanglian Injection Powder ("SHL"). The overall increase in sales was also supported by continuous marketing efforts, an increase in new product offerings, as well as expansion of coverage to previously unaddressed rural markets. OTC pharmaceutical products generated $36.2 million in revenue during the third quarter of 2009, in comparison to $37.8 million in the prior year's period, primarily reflecting lower sales performance of Jinji Yimucao, a drug included in China's Essential Drug list, as distribu...
Click here to read the whole Article (external link)

Earnings roundup: Tween Brands, Perfect World

Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....
Click here to read the whole Article (external link)

AMERICAN ORIENTAL BIOENGINEERING INC Files SEC form 10-Q, Quarterly Report

ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS All of the financial information presented in this Item 2 has been adjusted to reflect the restatement of our condensed consolidated financial statements for the three months ended September 30, 2008. Specifically, we have restated our condensed consolidated balance sheets as of September 30, 2008 and our condensed consolidated statements of operations and cash flows for the three months ended September 30,2008 as reported in the amended annual report on Form 10K/A for the fiscal year ended December 31, 2008. The restatement is fully described in the "Explanatory Note" immediately preceding Part I, Item 1of the amended annual report on Form 10K/A for December 31, 2008 filed concurrently with this report and in Note 3 to the condensed consolidated financial statements in this report. The following discussion should be read in conjunction with the information contained in the condensed consolidated financial statements of the Company and the notes thereto appearing elsewhere herein and in conjunction with the Management's Discussion and Analysis set forth in the Company's Annual Report on Form 10-K/A for the year ended December 31, 2008. Readers should carefully review the risk factors disclosed in the Company's Form 10-K/A for the year ended December 31, 2008 filed by the Company with the Securities and Exchange Commission (SEC).. As used in this report, the terms "Company", "we", "our", "us" and "AOB" refer to American Oriental Bioengineering, Inc., a Nevada corporation. PRELIMINARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This quarterly report contains forward-looking statements within the meaning of the federal securities laws. These include statements about our expectations, beliefs, intentions or strategies for the future, which we indicate by words or phrases such as "anticipate," "e...
Click here to read the whole Article (external link)

American Oriental Bioengineering 3Q profit falls

Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....
Click here to read the whole Article (external link)

Investors Find Fat Gains in Nutrition Stocks

Recent news in the nutrition sector helped select stocks buck the market on Tuesday. Obesity is a problem in the United States, and with a growing mainstream push for healthy living, a number of U.S.-listed nutrition stocks could see some upside. Today, isolated news is sending shares of select stocks up as much as 8% as the industry closes the gap on the S&P 500.As a whole, the Nutrition Product Stocks Index is up by 1.6%. It is currently lagging the S&P by -4% over the last month, however a look at the Index's six-month chart shows that it has remained ahead of the benchmark consistently over the longer time horizon.Excluding a -4% drop by American Oriental Bioengineering (NYSE: AOB - News), whose products range from prescription antivirals to soy-based wellness enhancing drinks and tablets, the sector is largely moving higher for the session.Mannatech (NASDAQ: MTEX - News) announced a new line of PhytoBurst soft chews - ...
Click here to read the whole Article (external link)

AMERICAN ORIENTAL BIOENGR INC Earnings Call scheduled for 8:00 am ET today

Call DetailsAMERICAN ORIENTAL BIOENGR INC Earnings Conference Call (Q3 2009)Tue, Nov 17, 2009, 8:00 am EasternAbout AMERICAN ORIENTAL BIOENGR INC (NYSE:AOB)American Oriental Bioengineering, Inc., along with its subsidiaries, engages in the development, manufacture, and commercialization of a range of pharmaceutical and healthcare products. It offers prescription and over-the-counter pharmaceutical products, and nutraceutical products. The company’s prescription pharmaceutical products include Shuanghuanlian Lyophilized (SHL) injection powder, an anti-viral injection for the treatment of flu symptoms, upper respiratory infections, mild pneumonia, and tonsillitis; and Cease Enuresis Soft Gel (CE Gel) to alleviate pediatric bedwetting. American Oriental Bioengineering markets the SHL products under SHJ brand name; the CE Gel under the brand name, Three Happines; and AOBO-001, an oral capsule developed from traditional Chinese herbal medicine for the treatment of urinary incontinence, which is in the phase one clinical trial. Its over-the-counter pharmaceutical products comprise Cease Enuresis Patch for the treatment of bedwetting and incontinence; Jinji Capsule for the treatment of endometritis, annexitis, and pelvic inflammations; Jinji Yimucao for the treatment of premenstrual syndrome (PMS), and other PMS and menopause-related symptoms; and Boke nasal spray for the treatment of sinus congestion from common cold, stuffy nose, chronic rhinitis, allergic rhinitis, and nasosinusitis. The company’s nutraceutical products include soybean peptide based drinks, tablets, powder, and instant coffee for health and well-being. American Oriental Bioengineering sells its products primarily to hospitals, clinics, pharmacies, and retail outlets in China. The company is based in Shenzhen, the People’s Republic of China.More Info:...
Click here to read the whole Article (external link)